The effect of combining antibiotics on resistance: A systematic review and meta-analysis

Berit Siedentop[1,2*], Viacheslav N. Kachalov[2,3], Christopher Witzany[1], Matthias Egger[4,5,6], Roger D. Kouyos[2,3†], Sebastian Bonhoeffer[1*†]

[1] Institute of Integrative Biology, Department of Environmental Systems Science, ETH Zürich, Zurich, Switzerland

[2] Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland

[3] Institute of Medical Virology, University of Zurich, Zurich, Switzerland

[4] Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland

[5] Population Health Sciences, University of Bristol, Bristol, UK

[6] Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

[†]These authors contributed equally

*Berit Siedentop, Sebastian Bonhoeffer

Email: berit.siedentop@env.ethz.ch, seb@env.ethz.ch

Author Contributions: SB, RDK, VNK, and BS conceived and designed the study. RDK and SB supervised the project. BS was responsible for the design of the literature search and the study protocol. VNK, RDK, SB, and ME reviewed the study protocol and approved it. VNK, CW, BS conducted the literature review, performed the data extraction. CW and BS assessed the quality of the studies. RDK, SB and BS conceptualised the statistical analysis. BS analysed the data. BS wrote the initial draft of the manuscript, which was revised by ME, RDK, CW and SB. All authors reviewed and approved the final version of the manuscript.

Competing Interest Statement: We declare no competing interests.

Keywords: antibiotic resistance, resistance evolution, combination therapy, meta-analysis, systematic review

Abstract

When and under which conditions antibiotic combination therapy decelerates rather than accelerates resistance evolution is not well understood. We examined the effect of combining antibiotics on within-patient resistance development across various bacterial pathogens and antibiotics.

We searched CENTRAL, EMBASE and PubMed for (quasi)-randomised controlled trials (RCTs) published from database inception to November 24th, 2022. Trials comparing antibiotic treatments with different numbers of antibiotics were included. A patient was considered to have acquired resistance if, at the follow-up culture, a resistant bacterium (as defined by the study authors) was detected that had not been present in the baseline culture. We combined results using a random effects model and performed meta-regression and stratified analyses. The trials' risk of bias was assessed with the Cochrane tool.

42 trials were eligible and 29, including 5054 patients, were qualified for statistical analysis. In most trials, resistance development was not the primary outcome and studies lacked power. The combined odds ratio (OR) for the acquisition of resistance comparing the group with the higher number of antibiotics with the comparison group was 1.23 (95% CI 0.68-2.25), with substantial between-study heterogeneity (I^2=77%). We identified tentative evidence for potential beneficial or detrimental effects of antibiotic combination therapy for specific pathogens or medical conditions.

The evidence for combining a higher number of antibiotics compared to fewer from RCTs is scarce and overall, is compatible with both benefit or harm. Trials powered to detect differences in resistance development or well-designed observational studies are required to clarify the impact of combination therapy on resistance.

Main Text

Introduction

Antibiotics are one of the most significant advances in modern medicine, prescribed to treat various bacterial infections in both humans and animals and prevent infections, such as surgical site infections or opportunistic infections in immunocompromised individuals (1). However, this medical breakthrough is at risk due to the rising prevalence of antibiotic resistance and an inadequate pipeline of new antibiotics. This disturbing trend threatens to undermine the effectiveness of antibiotics and poses a severe challenge to public health worldwide (2, 3). Hence, we need a more prudent use of antibiotics, and where antibiotics are needed, we need treatment strategies that reduce the risk that resistance emerges or spreads. Different strategies

64 for the optimal use of antibiotics have been investigated theoretically and empirically (4-7).
65 Antibiotic combination therapy, i.e., the simultaneous administration of several antibiotics, is
66 frequently discussed as a promising strategy for avoiding resistance evolution (6-10). Importantly,
67 it is the standard of care for some bacterial pathogens, such as *H. pylori*, *Mycobacterium*
68 *tuberculosis* (Mtb), or *Mycobacterium leprae* (11-13). However, it is unclear whether the effect of
69 combination therapy on resistance is consistent for different pathogens.

70 There are several motivations for the use of antibiotic combination therapy, including to
71 broaden the antibiotic spectrum in empirical treatment and reducing antibiotic resistance
72 development (14, 15). The simultaneous occurrence of resistance mutations to multiple drugs is
73 less likely than resistance to single drugs. Combination therapy should, therefore, reduce the
74 development of resistance (10). This expectation is supported by viral infections such as HIV,
75 where multiple point mutations are required for resistance to combination antiviral therapy.
76 However, it is less clear to what extent this reasoning extends to antibiotic therapy, where the
77 same mechanism can facilitate bacterial survival against multiple antibiotics (16, 17), and where
78 horizontal transfer of resistance may occur. Indeed, the benefit of combining antibiotics for
79 reducing resistance is debated for bacterial infections (18). Using more antibiotics overall could
80 lead to more resistance, as overall antibiotic consumption correlates with resistance (19).

81 Two meta-analyses of randomised controlled trials (RCTs) comparing beta-lactam
82 monotherapy to beta-lactam and aminoglycoside combination therapy found no differences in
83 resistance development (4, 5). However, the effect of combining antibiotics on within-patient
84 resistance development across many bacterial pathogens and various antibiotic combinations
85 has not been addressed. Within-patient antibiotic resistance development, even if rare, may
86 contribute to the emergence and spread of resistance. We performed a systematic review and
87 meta-analysis to (i) test the effect of antibiotic combination therapy on within-patient resistance
88 development and (ii) evaluate which factors affect the performance of combination therapy, as
89 e.g. pathogen identity, treatment design and resistance assessment.

90 **Results**
91
92 The search identified 3082 articles, which decreased to 1837 after deduplication. A total of 488
93 studies were eligible for full-text review, of which 41 studies qualified for inclusion. The screening
94 of the citations of the 41 studies identified one additional eligible study (SI section 11.4), for a total
95 of 42 studies, 40 RCTs and two quasi-RCTs, where the allocation method used is not truly
96 random (figure 1, table 1) (20-61). Twenty-nine studies could be included in the meta-analysis; 13
97 were excluded due to zero events in both treatment arms.

The included studies were published between 1977 and 2021, with a median publication year of 1995 and few recent studies (figure 2 A). The development of antibiotic resistance was typically not the main outcome: only nine studies (21%) explicitly defined a resistance outcome (table 1, SI table S1). Consequently, most studies did not have the statistical power to detect differences in within-patient resistance development even if we assume that the effect on resistance development is large between treatment arms (figure 2 B, SI section 8). Twenty-two (52%) focused on a specific pathogen species (resistant *Acinetobacter baumannii*, *Escherichia coli*, *H. pylori*, Mtb, methicillin-resistant *Staphylococcus aureus* (MRSA), *Pseudomonas aeruginosa*, *Staphylococcus aureus*) or pathogen group (MAC, *Salmonella enterica* subsp. *enterica* serotype Thyphi, or *Salmonella enterica* subsp. *enterica* serotype Parthypi A).

The five most frequent reasons for antibiotic administration were treatment or prophylaxis of urinary tract infections (UTIs) (6 studies, 14%), MRSA (5 studies, 12%), *H.* pylori, MAC, and prophylaxis for hematological malignancy patients with four studies (10%) respectively. Twenty-three of the included studies (55%) compared treatment arms with at least one administered antibiotic in common; the remaining studies compared treatment arms with no overlap in administered antibiotics (table 1). For the outcome acquisition of resistance, only two of all 42 studies had a low overall risk of bias according to the risk of bias assessment. Twelve (29%) were at high risk of bias, 28 (67%) at moderate risk of bias (SI section 3).

The overall pooled OR for acquisition of resistance comparing a lower number of antibiotics versus a higher one was 1.23 (95% CI 0.68 – 2.25), with substantial heterogeneity between studies (I^2 =77.4%). The latter OR was compatible with the OR for *de novo* emergence of resistance (pooled OR 0.74, 95% CI 0.34 – 1.59; I^2=77%). The overall pooled estimates are based on studies that focus on various clinical conditions/pathogens and compare different antibiotics treatments. To explore the impact of these and other potential sources of heterogeneity on the resistance estimates we performed sub-group analyses and meta-regression. The results for the two resistance outcomes are qualitatively comparable in the sense that individual estimates may differ, but show overall similar absence of evidence to support either benefit, harm or equivalence of treating with a higher number of antibiotics. Therefore, our focus in the following is on the acquisition of resistance (details on emergence of resistance can be found in the SI sections 1-8).

Stratified analyses revealed that a higher number of antibiotics performed better than a lower number in case of *H. pylori*, (pooled OR 0.14, 95% CI 0.03 – 0.55; I^2 =41.7%, figure 3A), and *MAC* (pooled OR 0.18, 95% CI 0.06 – 0.52; I^2 =26.8%, figure 3A), but worse in case of *P. aeruginosa* (pooled OR 3.42, 95% CI 1.03 – 11.43; I^2=1.54%, figure 3A). Furthermore, a lower

132 number of antibiotics performed better than a higher number if the compared treatment arms had
133 no antibiotics in common (pooled OR 4.73, 95% CI 2.14 – 10.42; I^2=37%, SI table S3), which
134 could be due to different potencies or resistance prevalences of antibiotics as discussed in SI (SI
135 section 6.1.10). In contrast, when restricting the analysis to studies with at least one common
136 antibiotic in the treatment arms we found no evidence of a difference, only a weak indication that
137 a higher number of antibiotics performs better (pooled OR 0.55, 95% CI 0.28 – 1.07; I^2 =74%,
138 figure 3B). When considering only resistance measurements of antibiotics common to both
139 treatment arms instead of all resistance measurements, the arm with a higher number of
140 antibiotics shows a benefit in comparison to the one with fewer (pooled OR 0.39, 95% CI 0.18 –
141 0.81; I^2=75%, SI p 6). If the study measured the acquisition of resistance of both gram negative
142 and positive bacteria, fewer antibiotics performed better (pooled OR 3.38, 95% CI 1.08 – 10.58;
143 I^2=38.35%, SI p 5). Other sub-group analyses did not show any harm or benefit of using a higher
144 number of antibiotics. The results for all subgroup analyses are presented in the supplement (SI
145 section 6). The multi-model inference for our meta-regression showed that the only significant
146 factor influencing the outcome acquisition of resistance is whether at least one common antibiotic
147 was used in the comparator arms (for details see SI section 7).

148 The inspection of the funnel plot and the modified Egger's test showed no indication of a
149 publication bias (SI section 5). The results were largely robust to the choice of the random effects
150 model (SI section 4). The probability of the secondary outcome "alterations of the prescribed
151 treatment due to adverse events", was higher using more antibiotics in comparison to fewer
152 (pooled OR 1.61, 95% CI 1.12 – 2.31; I^2=5%; SI p 10). In 15 studies (36%), the proportion of
153 patients with alterations of the prescribed treatment due to adverse events was reported, with
154 three studies (20%) reporting zero cases in both treatment arms. All other analyses of secondary
155 outcomes showed no indication of harm or benefit of treating with a higher number of antibiotics
156 (SI section 9).

157 **Discussion**
158
159 We performed a meta-analysis of RCTs and quasi-RCTs not limited to a particular
160 bacterial species, specific condition, or antibiotic combinations to assess the effect of antibiotic
161 combination therapy on within-patient resistance development. Our analysis could not identify any
162 benefit or harm of using a higher or a lower number of antibiotics regarding within-patient
163 resistance development. However, we found some evidence that combining antibiotics may be
164 beneficial or harmful for specific pathogens or infection types. Acquisition of resistance was rarely
165 a primary objective of the included RCTs. Hence, they were typically not designed to detect
166 differences in resistance development between treatment arms and underpowered for this
167 endpoint. Therefore, the absence of evidence does not mean that there is convincing evidence

168 for the lack of an effect of using more or fewer antibiotics on resistance development but rather
169 highlights a knowledge gap. This is remarkable given that the general rise of resistance is an
170 increasing concern (3, 18) and a priority area for health policy and public health (62).

171 Our analysis showed that combining antibiotics reduced resistance development for *H.*
172 *pylori* or MAC, in line with the current standard of care (11, 63). Surprisingly, we found only two
173 studies that satisfied our inclusion criteria for Mtb (24, 40), which may be considered the prime
174 example of effective antibiotic combination therapy. The limited number of Mtb studies may be
175 because antibiotic administration commonly varies during Mtb treatment, which conflicted with our
176 inclusion criteria that necessitated a consistent treatment regimen for susceptibility
177 measurements (SI section 2). Both eligible Mtb studies were excluded from the analysis due to
178 the absence of any events in either treatment arm.

179 Our main result, the absence of a general effect of combining antibiotics on resistance
180 development, aligns with the two previous meta-analyses (4, 5). With 42 trials in our systematic
181 review and 29 in the meta-analysis, our study provided a comprehensive assessment of the effect
182 of antibiotic combination therapy on within-patient resistance. Whereas previous meta-analyses
183 focused on a combination of specific antibiotic classes and included fewer than ten studies each,
184 our study aimed to assess the general effect of combining antibiotics on resistance evolution
185 across different bacterial pathogens. By including trials with different antibiotic combinations and
186 bacterial pathogens, we increased clinical and statistical heterogeneity. We accounted for many
187 sources of heterogeneity using stratification and meta-regression, but analyses were limited by
188 missing information and sparse data.

189 Our findings have implications for the design of future studies of resistance development.
190 Generally, the development of resistance within a patient is a rare event. However, even small
191 differences could be relevant at the population level. To obtain reliable estimates of such
192 differences and to better understand the factors influencing them, very large RCTs would be
193 needed, which systematically investigate the development of antibiotic resistance and include
194 resistance testing of each administered antibiotic. 19 (45%) of our included studies compared
195 treatment arms with no antibiotics in common, and 22 studies (52%) had more than one antibiotic
196 not identical in the treatment arms (table 1). To better evaluate the effect of combination therapy,
197 especially more RCTs would be needed where the basic antibiotic treatment is consistent across
198 both treatment arms, i.e. the antibiotics used in both treatment arms should be identical, except
199 for the additional antibiotic added in the comparator arm (table 1). As such RCTs are costly and
200 associated with high hurdles, the analysis of cohort studies could be an alternative approach.
201 Over 25 years ago, Fish et al. published a systematic summary of prospective observational

202 studies reporting data on resistance development, including antibiotic combination therapy (64).
203 Similarly, today, relevant cohort studies could be analysed collaboratively using various modern
204 statistical methods to address confounding by indication and other biases (65, 66). However,
205 even with appropriate causal inference methods, residual confounding cannot be excluded when
206 using observational data (67). Therefore, RCTs will remain the gold standard to estimate causal
207 relationships.

208 The main strength of this study is its comprehensive and systematic approach. For one, it
209 allowed identifying a knowledge gap regarding the effect of antibiotic combination therapy on
210 resistance development. Further, our study highlights several issues in the evidence base
211 evaluating antibiotic combination therapy and resistance development. The included trials did not
212 always test and report systematically the susceptibility against all administered antibiotics (table
213 1). Some antibiotics might have had reduced potency or were ineffective due to pre-existing
214 resistance mutations. Furthermore, in studies where treatment was not targeted against a specific
215 pathogen, some antibiotics may have been inactive against the causative pathogen due to
216 intrinsic resistance. Indeed, one of the reasons for using combination therapy is to broaden the
217 bacterial spectrum for empirical therapy (15), which could contribute to an increased risk of
218 antibiotic resistance spread.

219 Our study had several limitations. First, despite our systematic search, we might have
220 missed relevant studies. Since resistance development is typically not a primary endpoint and
221 often not reported systematically, relevant trials are challenging to identify. Our search strategy
222 aimed to identify a broad range of trials considering resistance development. However, as a
223 trade-off, our search strategy might have missed trials addressing a specific medical condition or
224 drug combination. Second, our systematic review and meta-analysis included many older studies
225 that did not follow the relevant reporting guidelines (68), thereby hampering data extraction and
226 potentially introducing bias. Third, it is often challenging to discern the specific mechanisms by
227 which resistance develops based on the data from clinical trials. This includes distinguishing
228 whether resistance arises *de novo*, if the pathogen acquires resistance through horizontal gene
229 transfer, if the patient becomes newly infected with a resistant pathogen, or if the pathogen was
230 present but undetected at the beginning of treatment. These scenarios can impact the
231 effectiveness of combination therapy. For example, combination therapy may be more likely to
232 select any pre-existing resistant pathogens compared to monotherapy due to the use of multiple
233 antibiotics. We addressed some of this heterogeneity by employing two different measures of
234 resistance (SI section 1). Furthermore, the variation in standards that classify bacteria as
235 susceptible or resistant adds another layer of heterogeneity alongside the technical limitations in
236 detecting resistance development.

In conclusion, combination therapy offers potential advantages and disadvantages regarding resistance evolution and spread. On the one hand, combination therapy typically increases the genetic barrier to resistance, and it has become the standard therapy for pathogens notorious for resistance evolution. Therefore, combination therapy remains a plausible candidate strategy to slow down resistance evolution. On the other hand, combination therapy generates selection pressure for resistance to multiple antibiotics simultaneously and could, therefore, accelerate resistance evolution – especially in the microbiome. Given the critical nature of this context, it is profoundly disconcerting that there is a lack of evidence elucidating the impact of combining antibiotics on the development of resistance.

Materials and Methods

Inclusion criteria and search strategy

We did a systematic review and meta-analysis to summarise the evidence on the effect of antibiotic combination therapy on resistance development. We included RCTs and quasi-RCTs comparing treatments with a higher number of antibiotics to treatments with a lower number of antibiotics. Studies were classified as quasi-RCTs if the allocation of participants to study arms was not truly random. We did not consider antiseptics or compounds supporting the activity of antibiotics, such as beta-lactam inhibitors as antibiotics itself. Whereas the antibiotic substances administered within one treatment arm had to be the same for all patients, the antibiotics could differ between treatment arms. We required baseline and follow-up cultures with resistance measurements to determine the treatment impact on resistance. We considered only antibiotic treatment regimens fixed for the period between two resistance measurements. Hence, we excluded sequential and cycling regimens.

We searched PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception up to 24.11.2022, using keywords, medical subject headings (MeSH), and EMTREE terms related to bacterial infection, antibiotics, combination therapy, resistance and RCTs. We excluded complementary and alternative medicine and bismuth. The search strategy is detailed in the SI (section 11). After a systematic deduplication process (69), VNK (or CW) and BS independently screened the titles and abstracts, and, if potentially eligible, the full texts. Any discrepancies between VNK (or CW) and BS were discussed and resolved. At full-text screening, we excluded articles that were not accessible in English or German. We screened the references of eligible studies and the trials included in two previous meta-analyses (4, 5). We followed the PRISMA reporting guidelines (70) and registered our protocol with PROSPERO (CRD42020187257).

272 **Outcomes**

273 We used two definitions for the primary outcome resistance. A broader definition, "acquisition of
274 resistance", and a stricter "*de novo* emergence of resistance" definition, where the latter is a
275 subset of the former. A patient was considered to have acquired resistance if, at the follow-up
276 culture, a resistant bacterium (as defined by the study authors) was detected that was not present
277 in the baseline culture. *De novo* emergence of resistance was defined as the detection of a
278 resistant bacterium that was present at baseline but sensitive. Additional secondary outcomes
279 included mortality from all causes and infection, treatment failure overall, treatment failure due to
280 resistance, treatment change due to adverse effects, and acquisition/*de novo* emergence of
281 resistance against non-administered antibiotics. The SI (section 9) provides further details.

282 **Data extraction and analysis**

283 VNK (or CW) and BS independently extracted all study data using a standardised form (see
284 https://osf.io/gwefy/?view_only=f6a4c1f4c79241038b203bd03c8e1845). The data extracted
285 included the proportion of patients who developed the two primary outcomes and the secondary
286 outcomes and study characteristics such as type of trial (RCT or quasi-RCT), follow-up and
287 treatment duration, number of antibiotics in the treatment arms, type of antibiotic, and presence of
288 comorbidities. Any discrepancies in data extraction were discussed and resolved.

289 We calculated odds ratios (ORs) with 95% confidence intervals (CIs), comparing a higher
290 with a lower number of antibiotics for each study. We combined ORs using a modified version of
291 the Simmonds and Higgins random effects model (71). If a study had more than two eligible
292 treatment arms, they were merged for statistical analysis. Studies with zero events in both
293 treatment arms were excluded from the statistical analysis. We used subgroup analyses and
294 meta-regressions with multi-model inference to examine the influence of pre-specified variables
295 on summary ORs. Variables included whether the antibiotic(s) used in the arm with the lower
296 number of antibiotics are also part of the arm(s) with the higher number of antibiotics, the number
297 of antibiotics administered, the age of the antibiotics (time since market entry), the administration
298 of other non-antibiotic drugs, whether participants had specific comorbidities or were in intensive
299 care, gram-status of the tested pathogens, and the length of antibiotic treatment and follow-up.
300 We extended our predefined analysis regarding the reason for antibiotic treatment/type of
301 pathogen, which was initially restricted to only *H. pylori* and Mtb, as we found enough studies to
302 stratify by other conditions/pathogens. We furthermore performed post-hoc subgroup analyses to
303 examine the following factors: treatment of resistant pathogens, additional antibiotic
304 administration besides the fixed treatment, and the way of antibiotic administration (SI section
305 6.2).

Between study heterogeneity was estimated with I^2, using the criteria for I^2 specified in Higgins et al. for classifying the degree of heterogeneity (72). CW and BS assessed each study's quality for the main outcomes using the Risk of Bias tool (RoB 2, SI section 3) (73). To assess publication bias, we visually inspected the funnel plot and a modified Egger's test (SI section 5). We performed sensitivity analyses on the model choice (SI section 4.1), and risk of bias (SI section 4.2), and performed a post-hoc trial sequential analysis (SI section 8.3). Statistical analyses and visualisations were done in R (version 4.2.1) using packages *metafor* and *MuMIn* (74, 75).

Acknowledgments

Support from the Swiss National Science Foundation (grant 310030B_176401 (SB, BS, CW), grant 32FP30-174281 (ME), grant 324730_207957 (RDK)) and from the National Institute of Allergy and Infectious Diseases (NIAID, cooperative agreement AI069924 (ME)) is gratefully acknowledged. We thank Anthony Hauser, João Pires and Frédérique Lachmann for helpful discussions and Annelies Zinkernagel and Johannes Nemeth for critical reading of the manuscript. Furthermore, we are grateful for all contacted study authors that responded to our inquiries and provided further information.

References

1. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. Journal of Clinical Oncology. 2018;36(30):3043-54.
2. Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Current Opinion in Microbiology. 2019;51:72-80.
3. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022;399(10325):629-55.
4. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of Aminoglycoside and β-Lactam Combination Therapy versus β-Lactam Monotherapy on the Emergence of Antimicrobial Resistance: A Meta-analysis of Randomized, Controlled Trials. Clinical Infectious Diseases. 2005;41(2):149-58.
5. Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database of Systematic Reviews. 2014(1).
6. Angst DC, Tepekule B, Sun L, Bogos B, Bonhoeffer S. Comparing treatment strategies to reduce antibiotic resistance in an in vitro epidemiological setting. Proceedings of the National Academy of Sciences. 2021;118(13):e2023467118.
7. Tepekule B, Uecker H, Derungs I, Frenoy A, Bonhoeffer S. Modeling antibiotic treatment in hospitals: A systematic approach shows benefits of combination therapy over cycling, mixing, and mono-drug therapies. PLOS Computational Biology. 2017;13(9):e1005745.
8. Sullivan GJ, Delgado NN, Maharjan R, Cain AK. How antibiotics work together: molecular mechanisms behind combination therapy. Current Opinion in Microbiology. 2020;57:31-40.
9. Tyers M, Wright GD. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nature Reviews Microbiology. 2019;17(3):141-55.

350 10. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic
351 resistance. Proceedings of the National Academy of Sciences. 1997;94(22):12106-11.
352 11. De Francesco V, Bellesia A, Ridola L, Manta R, Zullo A. First-line therapies for
353 Helicobacter pylori eradication: a critical reappraisal of updated guidelines. Ann Gastroenterol.
354 2017;30(4):373-9.
355 12. Singh R, Dwivedi SP, Gaharwar US, Meena R, Rajamani P, Prasad T. Recent updates on
356 drug resistance in Mycobacterium tuberculosis. Journal of Applied Microbiology.
357 2020;128(6):1547-67.
358 13. Alemu Belachew W, Naafs B. Position statement: LEPROSY: Diagnosis, treatment and
359 follow-up. Journal of the European Academy of Dermatology and Venereology.
360 2019;33(7):1205-13.
361 14. Pletz MW, Hagel S, Forstner C. Who benefits from antimicrobial combination therapy?
362 The Lancet Infectious Diseases. 2017;17(7):677-8.
363 15. Roemhild R, Bollenbach T, Andersson DI. The physiology and genetics of bacterial
364 responses to antibiotic combinations. Nature Reviews Microbiology. 2022.
365 16. Du D, Wang-Kan X, Neuberger A, van Veen HW, Pos KM, Piddock LJV, et al. Multidrug
366 efflux pumps: structure, function and regulation. Nature Reviews Microbiology. 2018;16(9):523-
367 39.
368 17. Lázár V, Snitser O, Barkan D, Kishony R. Antibiotic combinations reduce Staphylococcus
369 aureus clearance. Nature. 2022;610(7932):540-6.
370 18. Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al.
371 Understanding the mechanisms and drivers of antimicrobial resistance. The Lancet.
372 2016;387(10014):176-87.
373 19. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in
374 Europe and association with resistance: a cross-national database study. The Lancet.
375 2005;365(9459):579-87.
376 20. Bender JF, Schimpff SC, Young VM, Fortner CL, Brouillet MD, Love LJ, et al. Role of
377 vancomycin as a component of oral nonabsorbable antibiotics for microbial suppression in
378 leukemic patients. Antimicrobial agents and chemotherapy. 1979;15(3):455-60.
379 21. Black RE, Levine MM, Clements ML, Cisneros L, Daya V. Treatment of experimentally
380 induced enterotoxigenic Escherichia coli diarrhea with trimethoprim, trimethoprim-
381 sulfamethoxazole, or placebo. Reviews of infectious diseases. 1982;4(2):540-5.
382 22. Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart C, et al. Clarithromycin and
383 ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium
384 complex disease in patients with HIV infection. AIDS (london, england). 1997;11(3):311-7.
385 23. Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, et al. Prospective
386 randomized comparison of imipenem monotherapy with imipenem plus netilmicin for
387 treatment of severe infections in nonneutropenic patients. Antimicrobial agents and
388 chemotherapy. 1994;38(6):1309-13.
389 24. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, et al. Efficiency
390 and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during
391 the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial
392 in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet (london,
393 england). 2015;385(9979):1738-47.

394 25. Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a
395 comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Annals of internal
396 medicine. 1987;106(1):7-11.
397 26. Dickstein Y, Lellouche J, Schwartz D, Nutman A, Rakovitsky N, Dishon Benattar Y, et al.
398 Colistin Resistance Development Following Colistin-Meropenem Combination Therapy vs.
399 Colistin Monotherapy in Patients with Infections Caused by Carbapenem-Resistant Organisms.
400 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
401 2019.
402 27. Dubé MP, Sattler FR, Torriani FJ, See D, Havlir DV, Kemper CA, et al. A randomized
403 evaluation of ethambutol for prevention of relapse and drug resistance during treatment of
404 Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy.
405 Journal of Infectious Diseases. 1997;176(5):1225-32.
406 28. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al.
407 Colistin and rifampicin compared with colistin alone for the treatment of serious infections due
408 to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.
409 Clinical infectious diseases. 2013;57(3):349-58.
410 29. Fournier S, Burguière AM, Flahault A, Vincent V, Treilhou MP, Eliaszewicz M. Effect of
411 adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium
412 complex septicemia in AIDS patients. European journal of clinical microbiology & infectious
413 diseases. 1999;18(1):16-22.
414 30. Gerecht WB, Henry NK, Hoffman WW, Muller SM, LaRusso NF, Rosenblatt JE, et al.
415 Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and
416 gentamicin therapy for patients with cholangitis. Archives of internal medicine.
417 1989;149(6):1279-84.
418 31. Gibson J, Date L, Joshua DE, Young GA, Wilson A, Benn R, et al. A randomised trial of
419 empirical antibiotic therapy in febrile neutropenic patients with hematological disorders:
420 ceftazidime versus azlocillin plus amikacin. Australian and new zealand journal of medicine.
421 1989;19(5):417-25.
422 32. Haase DA, Harding GK, Thomson MJ, Kennedy JK, Urias BA, Ronald AR. Comparative trial
423 of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized,
424 acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal
425 microflora. Antimicrobial agents and chemotherapy. 1984;26(4):481-4.
426 33. Harbarth S, von Dach E, Pagani L, Macedo-Vinas M, Huttner B, Olearo F, et al.
427 Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin
428 versus linezolid for the treatment of MRSA infection. Journal of antimicrobial chemotherapy.
429 2015;70(1):264-72.
430 34. Hodson ME, Roberts CM, Butland RJ, Smith MJ, Batten JC. Oral ciprofloxacin compared
431 with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with
432 cystic fibrosis. Lancet (london, england). 1987;1(8527):235-7.
433 35. Hoepelman IM, Rozenberg-Arska M, Verhoef J. Comparative study of ceftriaxone
434 monotherapy versus a combination regimen of cefuroxime plus gentamicin for treatment of
435 serious bacterial infections: the efficacy, safety and effect on fecal flora. Chemotherapy. 1988;34
436 Suppl 1:21-9.
437 36. Hultén K, Jaup B, Stenquist B, Engstrand L. Combination treatment with ranitidine is
438 highly efficient against Helicobacter pylori despite negative impact of macrolide resistance.
439 Helicobacter. 1997;2(4):188-93.

440 37. Iravani A, Richard GA, Baer H, Fennell R. Comparative efficacy and safety of nalidixic acid
441 versus trimethoprim/sulfamethoxazole in treatment of acute urinary tract infections in college-
442 age women. Antimicrobial agents and chemotherapy. 1981;19(4):598-604.
443 38. Jacobs RF, Vats TS, Pappa KA, Chaudhary S, Kletzel M, Becton DL. Ceftazidime versus
444 ceftazidime plus tobramycin in febrile neutropenic children. Infection. 1993;21(4):223-8.
445 39. Jo JH, Harkins CP, Schwardt NH, Portillo JA, Zimmerman MD, Carter CL, et al. Alterations
446 of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics.
447 Sci Transl Med. 2021;13(625):eabd8077.
448 40. Macnab MF, Bohmer PD, Seager JR. Evaluation of the 3-drug combination, Rifater,
449 versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. South African
450 medical journal. 1994;84(6):325-8.
451 41. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with
452 vancomycin for the treatment of Staphylococcus aureus infection. Annals of internal medicine.
453 1992;117(5):390-8.
454 42. Mavromanolakis E, Maraki S, Samonis G, Tselentis Y, Cranidis A. Effect of norfloxacin,
455 trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent
456 urinary tract infections. Journal of chemotherapy (florence, italy). 1997;9(3):203-7.
457 43. May T, Brel F, Beuscart C, Vincent V, Perronne C, Doco-Lecompte T, et al. Comparison of
458 combination therapy regimens for treatment of human immunodeficiency virus-infected
459 patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium
460 Group. Agence Nationale de Recherche sur le Sida. Clinical infectious diseases. 1997;25(3):621-
461 9.
462 44. McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W, et al. Comparison of
463 piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in
464 children with cystic fibrosis. Pediatric pulmonology. 1988;4(4):201-4.
465 45. Menon R, Roberts FE, Barr KW, Howard H, Lord VL, Hegarty MA, et al. Comparison of a
466 slow-release trimethoprim with co-trimoxazole: efficacy and selection of resistance in the
467 Enterobacteriaceae. Journal of antimicrobial chemotherapy. 1986;18(3):415-20.
468 46. Miehlke S, Meining A, Lehn N, Höchter W, Weingart J, Simon T, et al. Comparison of
469 omeprazole, metronidazole and clarithromycin with omeprazole/amoxicillin dual-therapy for
470 the cure of Helicobacter pylori infection. Digestion. 1998;59(6):646-50.
471 47. Parras F, Guerrero MC, Bouza E, Blázquez MJ, Moreno S, Menarguez MC, et al.
472 Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication
473 of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrobial agents and
474 chemotherapy. 1995;39(1):175-9.
475 48. Parry MF, Neu HC, Merlino M, Gaerlan PF, Ores CN, Denning CR. Treatment of
476 pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and
477 gentamicin. J Pediatr. 1977;90(1):144-8.
478 49. Parry CM, Ho VA, Phuong le T, Bay PV, Lanh MN, Tung le T, et al. Randomized controlled
479 comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for
480 treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrobial agents
481 and chemotherapy. 2007;51(3):819-25.
482 50. Paul M, Bishara J, Yahav D, Goldberg E, Neuberger A, Ghanem-Zoubi N, et al.
483 Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin
484 resistant Staphylococcus aureus: randomised controlled trial. BMJ (clinical research ed).
485 2015;350:h2219.

486 51. Pogue JM, Rybak MJ, Stamper K, Marchaim D, Thamlikitkul V, Carmeli Y, et al.
487 Emergence of Colistin Resistance in the OVERCOME Trial: Impact of Combination Therapy with
488 Meropenem. Open Forum Infectious Diseases. 2021;8(SUPPL 1):S418-S9.
489 52. Pujol M, Miró JM, Shaw E, Aguado JM, San-Juan R, Puig-Asensio M, et al. Daptomycin
490 Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus
491 Bacteremia and Endocarditis: A Randomized Clinical Trial. Clin Infect Dis. 2021;72(9):1517-25.
492 53. Rubinstein E, Lode H, Grassi C, Castelo A, Ward K, Alanko K, et al. Ceftazidime
493 monotherapy vs. Ceftriaxone/tobramycin for serious hospital- acquired gram-negative
494 infections. Clinical Infectious Diseases. 1995;20(5):1217-28.
495 54. Schaeffer AJ, Flynn S, Jones J. Comparison of cinoxacin and trimethoprim-
496 sulfamethoxazole in the treatment of urinary tract infections. Journal of urology.
497 1981;125(6):825-7.
498 55. Schaeffer AJ, Sisney GA. Efficacy of norfloxacin in urinary tract infection biological
499 effects on vaginal and fecal flora. Journal of urology. 1985;133(4):628-30.
500 56. Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, et al. Comparison of a
501 β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic
502 fibrosis. Journal of Pediatrics. 1999;134(4):413-21.
503 57. Stack WA, Knifton A, Thirlwell D, Cockayne A, Jenkins D, Hawkey CJ, et al. Safety and
504 efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of
505 Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. American
506 journal of gastroenterology. 1998;93(10):1909-13.
507 58. Walsh TJ, Standiford HC, Reboli AC, John JF, Mulligan ME, Ribner BS, et al. Randomized
508 double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole
509 against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial
510 resistance and effect of host factors on outcome. Antimicrobial agents and chemotherapy.
511 1993;37(6):1334-42.
512 59. Winston DJ, Ho WG, Nakao SL, Gale RP, Champlin RE. Norfloxacin versus
513 vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med.
514 1986;80(5):884-90.
515 60. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Ofloxacin versus
516 vancomycin/polymyxin for prevention of infections in granulocytopenic patients. American
517 journal of medicine. 1990;88(1):36-42.
518 61. Wurzer H, Rodrigo L, Stamler D, Archambault A, Rokkas T, Skandalis N, et al. Short-
519 course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates
520 Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. Alimentary pharmacology &
521 therapeutics. 1997;11(5):943-52.
522 62. Joshi LT. The G7 Summit 2021: time for our world leaders to step up to the challenge of
523 antimicrobial resistance. Access Microbiology. 2021;3(12).
524 63. Kerantzas Christopher A, Jacobs William R, Rubin Eric J, Collier RJ. Origins of
525 Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and
526 Application. mBio.8(2):e01586-16.
527 64. Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial
528 therapy: a review of antibiotic classes and patient characteristics in 173 studies.
529 Pharmacotherapy. 1995;15(3):279-91.
530 65. Hernán MA, Wang W, Leaf DE. Target Trial Emulation: A Framework for Causal Inference
531 From Observational Data. JAMA. 2022;328(24):2446-7.

66. Hernán MA. Methods of Public Health Research — Strengthening Causal Inference from Observational Data. New England Journal of Medicine. 2021;385(15):1345-8.
67. Schuster NA, Rijnhart JJ, Bosman LC, Twisk JW, Klausch T, Heymans MW. Misspecification of confounder-exposure and confounder-outcome associations leads to bias in effect estimates. BMC medical research methodology. 2023;23(1):11.
68. Schulz KF, Altman DG, Moher D, for the CG. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. PLOS Medicine. 2010;7(3):e1000251.
69. Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240-3.
70. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic Reviews. 2021;10(1):89.
71. Jackson D, Law M, Stijnen T, Viechtbauer W, White IR. A comparison of seven random-effects models for meta-analyses that estimate the summary odds ratio. Stat Med. 2018;37(7):1059-85.
72. Deeks JJ, Higgins JPT, Altman DG. Analysing Data and Undertaking Meta-Analyses. Chichester, UK: John Wiley & Sons, Ltd; 2008. p. 243-96.
73. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
74. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. Journal of Statistical Software. 2010;36(3):1 - 48.
75. Bartoń K. MuMIn: Multi-Model Inference. 2020.

Figures and Tables



Figure 1. Study selection



Figure 2. Measuring antibiotic resistance is not a current main objective of RCTs. A) Distribution of the publishing year of included studies, where n indicates the number of studies, and the red vertical line the median of the distribution. B) Calculated power of included studies to detect an odds ratio of 0.5. The power calculations were based on equal treatment arm sizes. For the calculations the treatment arm with the higher number of patients of the respective studies was used.



Figure 3. Forest plot of acquisition of bacterial resistance stratified by the reason antibiotics were administered. The coloring indicates the number of antibiotics that were compared in each study. A) The overall pooled LOR of all included studies. B) The pooled LOR of studies with at least one antibiotic in common in the treatment arms. UTI stands for urinary tract infection, MRSA for

methicillin-resistant *Staphylococcus aureus*, MAC for *Mycobacterium avium* complex, and BSI for blood stream infection.

Table 1. Overview of the 42 RCTs or quasi-RCTs included in the systematic review and meta-analysis. The underlined antibiotics indicate that resistance measurements were made for this antibiotic, reported and extractable from the studies. Justification for resistance outcome extraction is given in SI table S1.

Study	Type of Study	Focused pathogen/ Reason for antibiotic treatment	Objective(s)	Antibiotics used in study arms		Explicit Definition of Resistance Outcome	Secondary Outcomes extracted
				Less antibiotics	More Antibiotics		
Bender et al. (1979)(20)	RCT	Infection prophylaxis for patients with acute leukemia or malignant lymphomas receiving remission induction chemotherapy	Tolerance, suppression of microbial flora, protection against colonisation and infection	Gentamicin	Gentamicin, and vancomycin	no	All-cause mortality
Black et al. (1982)(21)	RCT	enterotoxigenic *Escherichia coli* (ETEC)	Compare two treatments options against ECET.	Trimethoprim	Trimethoprim, and sulfamethoxazole	no	-
Chaisson et al. (1997)(22)	RCT	MAC	Safety and activity	Clarithromycin, and ethambutol	Clarithromycin, ethambutol, and clofazimine	no	All-cause mortality
Cometta et al. (1994)(23)	RCT	Nosocomial pneumonia, nosocomial	Clinical efficacy and tolerance, emergence of	Imipenem	Imipenem, and netilmicin	no	Mortality attributable to infection,

		sepsis, or severe diffuse peritonitis	resistance and risk of superinfection				treatment failure, treatment failure due to a change of resistance against the study drugs
Dawson et al. (2015)(24)	RCT	Mtb	Efficacy, and safety	Moxifloxacin, pretomanid, and pyrazinamide	Isoniazid, rifampicin, pyrazinamide, and ethambutol	no	Proportion of patients with alterations of the prescribed treatment due to adverse events
Dekker et al. (1987)(25)	RCT	Prophylaxis for acute nonlymphocytic or lymphocytic leukemia	Efficacy of protecting against infections	Ciprofloxacin	Trimethoprim, and sulfamethoxazole	no	All-cause mortality, mortality attributable to infection, acquisition of resistance against non-administered antibiotics
Dickstein et al. (2019)(26)	RCT	Carbapenem resistant, colistin-susceptible, and gram-negative infections	Development of colistin resistance (secondary outcome of a clinical trial)	Colistin	Colistin, and meropenem	yes	All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events
Dubé et al. (1997)(27)	RCT	MAC	Risk of recrudescent MAC bacteraemia, emergence of resistance to clarithromycin.	Clarithromycin, and clofazimine	Clarithromycin, clofazimine, and ethambutol	no	All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events
Durante-Mangoni et al. (2013)(28)	RCT	Extensively drug resistant *Acinetobacter baumannii*	Mortality	Colistin	Colistin, and rifampicin	yes	All-cause mortality, mortality attributable to infection, treatment failure
Fournier et al. (1999)(29)	RCT	MAC	Efficacy and tolerance.	Clarithromycin, ethambutol	Clarithromycin, ethambutol, and clofazimine	no	All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events
Gerecht et al. (1989)(30)	RCT	Cholangitis	Compare a single drug treatment to a two-drug treatment.	Mezlocillin	Ampicillin, and gentamicin	yes	All-cause mortality, treatment failure as reported in each study, treatment failure due to a change of resistance against the study drugs

Gibson et al. (1989)(31)	RCT	Febrile neutropenia	Efficacy and side effects	Ceftazidime	Azlocillin, and amikacin	no	All-cause mortality, mortality attributable to infection, proportion of patients with alterations of the prescribed treatment due to adverse events, acquisition of resistance against non-administered antibiotics, emergence of resistance against non-administered antibiotics
Haase et al. (1984)(32)	RCT	UTI	Efficacy, tolerance, and safety	Norfloxacin	Trimethoprim, and sulfamethoxazole	no	Treatment failure, acquisition of resistance against non-administered antibiotics
Hartbarth et al. (2015)(33)	RCT	MRSA	Assess the non-inferiority of a multiple drug treatment in comparison of a single drug treatment.	Linezolid	Trimethoprim, sulfamethoxazole, and rifampicin	no	All-cause mortality, mortality attributable to infection, treatment failure
Hodson (1987)(34)	RCT	Cystic fibrosis patients with *P. aeruginosa*	Compare an oral one drug treatment to an intravenous two drug treatment.	Ciprofloxacin	Azlocillin, and gentamicin	no	-
Hoepelman et al. (1988)(35)	RCT	Serious bacterial infections	Emergence of resistance of fecal flora	Ceftriaxone	Cefuroxime, and gentamicin	no	Proportion of patients with alterations of the prescribed treatment due to adverse events
Hultén et al. (1997)(36)	RCT	*H. pylori*	Antibacterial efficacy, emergence of clarithromycin resistance.	Clarithromycin	Clarithromycin, and lymecycline	no	-
Iravani et al. (1981)(37)	RCT	Acute UTI	Efficacy, treatment effects on fecal flora, resistance emergence in the infecting pathogen	Nalidixic acid	Trimethoprim, and sulfamethoxazole	no	-
Jacobs et al. (1993)(38)	RCT	Bacterial infections in neutropenic children	Efficacy and safety, tolerance, emergence of resistance and risk of superinfection	Ceftazidime	Ceftazidime, and tobramycin	yes	All-cause mortality, treatment failure, treatment failure due to a change of resistance against the study drugs

Jo et al. (2021)(39)	RCT	Determine impact of antibiotics on healthy skin microbiota	Investigate short and long term of the skin microbiome	Doxcycycline	Trimethoprim, and sulfamethoxazole	no	-
Macnab et al. (1994)(40)	Quasi-RCT	Mtb	Efficacy, primary drug resistance, bacteriological conversion rates, compliance, and side effects	Isoniazid, and rifampicin	Isoniazid, rifampicin, and ethambutol	no	Proportion of patients with alterations of the prescribed treatment due to adverse event
Markowitz et al. (1992)(41)	RCT	*S. aureus*	Efficacy and safety	Vancomycin	Trimethoprim, and sulfamethoxazole	no	All-cause mortality, treatment failure, proportion of patients with alterations of the prescribed treatment due to adverse events
Mavromanolakis et al. (1997)(42)	RCT	Recurrent UTIs	Effect on the aerobic bowel flora, frequency of resistant strains in the fecal flora during and after treatment.	Norfloxacin, or Nitrofurantoin	Trimethoprim, and sulfamethoxazole	no	-
May et al. (1997)(43)	RCT	MAC	Clinical and bacteriological efficacy, safety, tolerability	Clarithromycin, and clofazimine	Clarithromycin, rifabutin, and ethambutol	no	All-cause mortality, treatment failure, proportion of patients with alterations of the prescribed treatment due to adverse events
Mc Carty et al. (1988)(44)	RCT	Cystic fibrosis patients with *P. aeruginosa*	Safety, pharmacokinetics of a high-dose singe drug treatment, the effectiveness	Piperacillin	Piperacillin, and tobramycin	no	All-cause mortality, mortality attributable to infection
Menon et al. (1986)(45)	RCT	Acute UTI	Efficacy, selection of resistance in Enterobacteriaceae	Trimethoprim	Trimethoprim, and sulfamethoxazole	no	Acquisition of resistance against non-administered antibiotics
Miehlke et al. (1998)(46)	RCT	*H. pylori*	Effectiveness, tolerability	Amoxicillin	Clarithromycin, and metronidazole	no	Proportion of patients with alterations of the prescribed treatment due to adverse events

Parras et al. (1995)(47)	RCT	MRSA	Efficacy to eradicate, safety	Mupirocin	Sodium fusidate, trimethoprim, and sulfamethoxazole	no	All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events
Parry et al. (1977)(48)	Quasi-RCT	*Pulmonary infection*	Effectiveness, treatment failure, treatment success, frequency of ticarcillin resistant organisms, influence of resistance on disease development	Ticarcillin	Ticarcillin, and gentamicin	no	-
Parry et al. (2007)(49)	RCT	Multidrug resistant typhoid fever	Efficacy	Ofloxacin, or Azithromycin	Ofloxacin, and Azithromycin	no	Treatment failure
Paul et al. (2015)(50)	RCT	MRSA	Test whether a two-drug treatment is non-inferior to a two-drug treatment.	Vancomycin	Trimethoprim, and sulfamethoxazole	yes	All-cause mortality, treatment failure, acquisition of resistance against non-administered antibiotics, emergence of resistance against non-administered antibiotics
Pogue et al. (2021)(51)	RCT	Gram negative resistant bloodstream infections or pneumonia	Assess superiority of a combination of colistin to monotherapy.	Colistin	Colistin, and meropenem	yes	All-cause mortality, treatment failure
Pujol et al. (2021)(52)	RCT	MRSA	Assess treatment success.	Daptomycin	Daptomycin, and fosfomycin	yes	All-cause mortality, treatment failure, proportion of patients with alterations of the prescribed treatment due to adverse events
Rubinstein et al. (1995)(53)	RCT	Gram-negative hospital acquired infections	Efficacy, safety	Ceftazidime	Ceftriaxone, and Tobramycin	yes	All-cause mortality, mortality attributable to infection, treatment failure, proportion of patients with alterations of the prescribed treatment due to adverse events
Schaeffer et al. (1981)(54)	RCT	UTI	Effectiveness, safety, incidence of resistance in faecal and vaginal flora	Cinoxacin	Trimethoprim, and sulfamethoxazole	no	Proportion of patients with alterations of the prescribed treatment due to adverse events

			before, and after treatment.				
Schaeffer et al. (1985)(55)	RCT	UTI	Effectiveness, safety, incidence of resistance in fecal and vaginal flora before, and after treatment.	Norfloxacin	Trimethoprim, and sulfamethoxazole	no	-
Smith et al. (1999)(56)	RCT	P. aeruginosa	Efficacy	Azlocillin	Azlocillin, and tobramycin	no	Acquisition of resistance against non-administered antibiotics, emergence of resistance against non-administered antibiotics
Stack et al. (1998)(57)	RCT	*H. pylori*	Efficacy, safety	Clarithromycin	Clarithromycin, and metronidazole, or amoxycillin	no	-
Walsh et al. (1993)(58)	RCT	MRSA	Efficacy of eradication, emergence of resistance, safety	Novobiocin, and rifampicin	Rifampicin, trimethoprim, and sulfamethoxazole	yes	Treatment failure, acquisition of resistance against non-administered antibiotics, emergence of resistance against non-administered antibiotics
Winston et al. (1986)(59)	RCT	Prophylaxis for hematological malignancy patients	Efficacy and safety	Norfloxacin	Vancomycin, and polymyxin	no	Mortality attributable to infection
Winston et al. (1990)(60)	RCT	Prophylaxis for hematological malignancy patients	Efficacy and safety	Ofloxacin	Vancomycin, and polymyxin	no	-
Wurzer et al. (1997)(61)	RCT	*H. pylori*	Effectiveness, emergence of resistance.	Clarithromycin	Clarithromycin, and amoxycillin	no	-